Menu
News
Quotes
Inhaled insulin is dead. Long live inhaled insulin?Pfizer took a $2.8 billion write-down today when it admitted defeat and cancelled Exubera, its inhaled insulin that hardly anybody bought. Stock of Pfizer’s Exubera partner, Nektar, fell more than 15% (see chart).Pfizer hoped Exubera would be a popular alternative for those diabetics who don’t like
Chart diabetic diet

<